HK1138297A1 - 丙型肝炎病毒 的人類抗體及其用途 - Google Patents

丙型肝炎病毒 的人類抗體及其用途

Info

Publication number
HK1138297A1
HK1138297A1 HK10105123.7A HK10105123A HK1138297A1 HK 1138297 A1 HK1138297 A1 HK 1138297A1 HK 10105123 A HK10105123 A HK 10105123A HK 1138297 A1 HK1138297 A1 HK 1138297A1
Authority
HK
Hong Kong
Prior art keywords
hcv
virus
human antibodies
antibodies against
against hepatitis
Prior art date
Application number
HK10105123.7A
Other languages
English (en)
Inventor
Teresa Broering
Susan Sloan
Gregory J Babcock
Donna Ambrosino
William D Thomas Jr
Original Assignee
Univ Massachusetts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Massachusetts filed Critical Univ Massachusetts
Publication of HK1138297A1 publication Critical patent/HK1138297A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK10105123.7A 2007-02-21 2010-05-25 丙型肝炎病毒 的人類抗體及其用途 HK1138297A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90243207P 2007-02-21 2007-02-21
PCT/US2008/001922 WO2008108918A1 (en) 2007-02-21 2008-02-13 Human antibodies against hepatitis c virus (hcv) uses thereof

Publications (1)

Publication Number Publication Date
HK1138297A1 true HK1138297A1 (zh) 2010-08-20

Family

ID=39537518

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10105123.7A HK1138297A1 (zh) 2007-02-21 2010-05-25 丙型肝炎病毒 的人類抗體及其用途

Country Status (22)

Country Link
US (2) US8551484B2 (zh)
EP (1) EP2125889B1 (zh)
JP (1) JP5642972B2 (zh)
KR (1) KR101518081B1 (zh)
CN (1) CN101679512A (zh)
AU (1) AU2008223561B2 (zh)
BR (1) BRPI0807929A2 (zh)
CA (1) CA2678888C (zh)
CY (1) CY1115282T1 (zh)
DK (1) DK2125889T3 (zh)
ES (1) ES2456961T3 (zh)
HK (1) HK1138297A1 (zh)
HR (1) HRP20140316T1 (zh)
IL (1) IL200432A (zh)
MX (1) MX2009008706A (zh)
NZ (1) NZ579706A (zh)
PL (1) PL2125889T3 (zh)
PT (1) PT2125889E (zh)
RS (1) RS53258B (zh)
SI (1) SI2125889T1 (zh)
WO (1) WO2008108918A1 (zh)
ZA (1) ZA200905762B (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009143345A2 (en) * 2008-05-22 2009-11-26 University Of Massachusetts Nucleic acid silencing agent-protein conjugates and use thereof for treating hcv-related disorders
WO2010035292A1 (en) * 2008-09-24 2010-04-01 Natimab Therapeutics S.R.L. The use of a human monoclonal anti-hcv antibody as a medicament for the therapeutic treatment and prevention of hcv infections
CA2658714A1 (en) * 2009-03-17 2010-09-17 Thomas Krey Hcv-derived polypeptides and uses thereof
PT2564695E (pt) 2009-07-08 2015-06-03 Kymab Ltd Modelos animais e moléculas terapêuticas
JP2014533930A (ja) * 2011-09-19 2014-12-18 カイマブ・リミテッド 免疫グロブリン遺伝子多様性の操作およびマルチ抗体治療薬
WO2013062507A1 (en) * 2011-10-24 2013-05-02 The Trustees Of The University Of Pennsylvania Improved hcv vaccines and methods for using the same
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
CA2925723A1 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
RU2539770C1 (ru) * 2013-12-27 2015-01-27 Татьяна Николаевна Власик Способ нейтрализации вируса гепатита с, полностью человеческое моноклональное антитело против вируса гепатита с (варианты), композиция полностью человеческих моноклональных антител против вируса гепатита с и гибридная мышь/человек клеточная линия - продуцент полностью человеческих моноклональных антител против вируса гепатита с (варианты)
CN105330730A (zh) * 2014-07-29 2016-02-17 中国科学院上海巴斯德研究所 一种丙型肝炎病毒重组蛋白的制备及其应用
PL230663B1 (pl) * 2015-01-15 2018-11-30 Univ Gdanski Szczepionka, sposob jej otrzymywania, wyizolowane chimeryczne bialko, wektor ekspresyjny, zestaw zawierajacy szczepionke oraz kompozycja do zastosowania w profilaktyce zakazen powodowanych przez HCV i/lub HBV
CN105254756B (zh) * 2015-11-27 2018-09-07 武汉大学 一种针对丙型肝炎病毒包膜蛋白e2的单克隆抗体及应用
CN107011435B (zh) 2016-06-01 2019-02-12 苏州银河生物医药有限公司 抗丙型肝炎病毒的全人单克隆抗体8d6
CN106749644B (zh) * 2016-11-14 2018-08-14 广州泰诺迪生物科技有限公司 一种全人源抗hcv的中和抗体-trn1001
EP3615054A4 (en) 2017-04-27 2021-03-24 The Trustees Of The University Of Pennsylvania NUCLEOSIDE-MODIFIED MRNA LIPID NANOPARTICLE VACCINE FOR HEPATITIS C VIRUS
CN109738648B (zh) * 2018-12-29 2021-09-17 山东莱博生物科技有限公司 稳定高效表达丙型肝炎病毒核心抗原抗体的工程细胞株及其应用
CN113138276B (zh) * 2020-01-19 2022-09-16 厦门万泰凯瑞生物技术有限公司 用于检测HBcAg的方法及抗体
KR20220140802A (ko) 2020-02-11 2022-10-18 리제너론 파아마슈티컬스, 인크. 항-acvr1 항체 및 이의 용도
BR112023016241A2 (pt) * 2021-02-12 2023-11-14 Merck Sharp & Dohme Llc Anticorpos que se ligam ao metapneumovírus, proteínas antigênicas de metapneumovírus e usos dos mesmos

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US6171782B1 (en) 1987-11-18 2001-01-09 Chiron Corporation Antibody compositions to HCV and uses thereof
US5879936A (en) 1988-04-18 1999-03-09 Aluguisse Holding A.G. Recombinant DNA methods, vectors and host cells
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5308750A (en) 1989-12-22 1994-05-03 Abbott Laboratories Monoclonal antibodies to putative HCV E2/NS1 proteins and methods for using same
US5891693A (en) 1990-01-25 1999-04-06 Alusuisse Holdings A.G. Recombinant DNA methods vectors and host cells
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
WO1992007001A1 (en) 1990-10-12 1992-04-30 Abbott Laboratories Hepatitis c virus antibody
ATE167522T1 (de) 1991-01-31 1998-07-15 Abbott Lab Monoklonale antikörper gegen mögliche hcv- hüllregionen und methoden diese zu benutzen
FR2677372B1 (fr) 1991-06-06 1994-11-10 Pasteur Institut Sequences nucleotidiques et peptidiques d'un isolat de virus de l'hepatite c, applications diagnostiques et therapeutiques.
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
EP0593592B1 (en) 1991-07-08 1998-03-25 The University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
CA2112667C (en) 1991-08-21 2004-02-17 Smriti U. Mehta Monoclonal antibodies to putative hcv ns5 proteins and methods for using same
ZA927837B (en) 1991-10-15 1994-03-11 Akzo Nv Monoclonal antibodiesto hepatitis C virus
JP2778886B2 (ja) 1992-10-16 1998-07-23 エバーニュー バイオテック インコーポレイティド Ｃ型肝炎ウィルスのコア抗原タンパク質及びそれを用いての診断方法及びキット
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
WO1995010603A1 (en) 1993-10-08 1995-04-20 Novo Nordisk A/S Amylase variants
EP1709970A1 (en) 1995-04-27 2006-10-11 Abgenix, Inc. Human antibodies against EGFR, derived from immunized xenomice
US6747136B2 (en) 1996-04-19 2004-06-08 Karolinska Innovations Ab Human monoclonal antibodies specific for hepatitis C virus (HCV) E2 antigen
AU738585B2 (en) 1996-11-08 2001-09-20 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Synthesis and purification of hepatitis C virus-like particles
JP2001522599A (ja) 1997-11-06 2001-11-20 イノジェネティックス・ナムローゼ・フェンノートシャップ 診断用及びワクチン用、ｃ型肝炎ウイルスエンベロープタンパク質由来マルチマーペプチド
EP0947525A1 (en) 1998-03-27 1999-10-06 Innogenetics N.V. Epitopes in viral envelope proteins and specific antibodies directed against these epitopes: use for detection of HCV viral antigen in host tissue
WO2000005266A1 (en) 1998-07-21 2000-02-03 Connex Gesellschaft Zur Optimierung Von Forschung Und Entwicklung Mbh Anti hepatitis c virus antibody and uses thereof
US20060188511A1 (en) 1998-11-05 2006-08-24 Foung Steven K Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes
AU1462300A (en) 1998-11-05 2000-05-22 Board Of Trustees Of The Leland Stanford Junior University Human pan-hcv human monoclonal antibodies
US20030180284A1 (en) * 1998-11-05 2003-09-25 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes
IL137522A (en) 2000-07-26 2007-06-17 Drk Blutspendediendst Baden Wu HCV human monoclonal antibody E2 glycoprotein antibody
EP1355947A2 (en) 2000-12-01 2003-10-29 The Government of the United States of America, as Represented by the Secretary, Department of Health and Human Services Monoclonal antibodies specific for the e2 glycoprotein of hepatitis c virus and their use in the diagnosis, treatment, and prevention of hepatitis c
WO2002060954A1 (en) 2001-01-12 2002-08-08 Karolinska Innovations Ab Materials and methods for treatment of hepatitis c
ITRM20010336A1 (it) 2001-06-13 2002-12-13 Biostrands S R L Anticorpo umano ricombinante diretto contro la proteina non strutturale ns3 del virus dell'epatite c (hcv), acido nucleico codificante e usi
CA2491471A1 (en) 2002-07-03 2004-01-15 The Trustees Of The University Of Pennsylvania Compositions, methods and kits relating to anti-platelet autoantibodies and inhibitors thereof

Also Published As

Publication number Publication date
SI2125889T1 (sl) 2014-06-30
US20120288510A1 (en) 2012-11-15
HRP20140316T1 (hr) 2014-05-09
ES2456961T3 (es) 2014-04-24
RS53258B (en) 2014-08-29
IL200432A0 (en) 2010-04-29
KR101518081B1 (ko) 2015-05-06
JP2010518854A (ja) 2010-06-03
CA2678888A1 (en) 2008-09-12
KR20100014476A (ko) 2010-02-10
CY1115282T1 (el) 2017-01-04
US8551484B2 (en) 2013-10-08
PL2125889T3 (pl) 2014-06-30
EP2125889B1 (en) 2014-01-15
MX2009008706A (es) 2009-09-14
PT2125889E (pt) 2014-04-15
JP5642972B2 (ja) 2014-12-17
CA2678888C (en) 2015-04-14
AU2008223561B2 (en) 2013-10-03
BRPI0807929A2 (pt) 2014-06-24
WO2008108918A1 (en) 2008-09-12
ZA200905762B (en) 2013-03-27
NZ579706A (en) 2012-03-30
AU2008223561A1 (en) 2008-09-12
US20140134175A1 (en) 2014-05-15
IL200432A (en) 2015-02-26
EP2125889A1 (en) 2009-12-02
CN101679512A (zh) 2010-03-24
DK2125889T3 (da) 2014-04-14

Similar Documents

Publication Publication Date Title
HK1138297A1 (zh) 丙型肝炎病毒 的人類抗體及其用途
HK1144440A1 (zh) 丙型肝炎病毒抗體
AP2907A (en) Viral hepatitis treatment
HK1126486A1 (zh) 丙型肝炎病毒 抑制劑
GB0718984D0 (en) Structure of the hepatitis C virus NS5A protein
IL194920A0 (en) Hepatitis c virus infection biomarkers
EP2062246A4 (en) CHIMERIC VIRAL VACCINES
IL212040A0 (en) Hepatitis c antibodies and uses thereof
EP2120988A4 (en) TREATMENT OF HEPATITIS C VIRUS INFECTIONS
HK1109069A1 (en) Vaccine composition against hepatitis c virus
EP1982728A4 (en) HEPATITIS C-VIRUS DERIVED PEPTIDE
EP2004684A4 (en) THE HEPATITIS C-VIRUS NEUTRALIZING ANTIBODIES
ZA200903379B (en) Hepatitis C virus inhibitors
SI2203430T1 (sl) N-fenil-diokso-hidropirimidini, uporabni kot inhibitorji virusa hepatitisa C (HCV)
GB0501582D0 (en) Hepatitis c virus replication system
HUS1500008I1 (hu) Hepatitis C vírus inhibitorok
GB0421916D0 (en) Hepatitis C virus replication system
AU2004904920A0 (en) Hepatitis C Virus Epitopes
ZA200903014B (en) Hepatitis C virus inhibitors

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180213